-
CSPC Pharmaceutical’s mRNA Vaccine SYS6006 Receives Emergency Use Authorization in China
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has revealed that it has obtained an Emergency Use Authorization (EUA) for its in-house developed COVID-19 mRNA vaccine, SYS6006, in China. This approval marks a significant milestone as it is the first for a domestically developed mRNA product in the country. SYS6006 Design…
-
Sihuan Pharmaceutical’s KM501 Receives Clinical Trial Approval for HER2-Positive Tumors
•
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its XZP-KM501 (KM501) in solid tumors with HER2 positive, middle to low-expression. This marks a significant step forward in the development of innovative treatments for…
-
4B Technologies’ FB1001 Receives CDE Approval for Clinical Trials
•
China-based 4B Technologies Investments Ltd has announced that it has received clinical trial approval from the Center for Drug Evaluation (CDE) for its potential first-in-class monoclonal antibody (mAb) FB1001 (ZG103). This marks a significant milestone in the development of the drug candidate, which was developed by the company’s founder, Dr.…
-
RemeGen’s RC48 Receives Two Clinical Trial Approvals for Breast Cancer Treatments
•
RemeGen Ltd (HKG: 9995) has announced the receipt of two clinical trial approvals for its antibody-drug conjugate (ADC) candidate RC48 (disitamab vedotin). The Chinese firm is set to assess the drug as a neo-adjuvant therapy for HR-positive, HER2 low-expression breast cancer, either in combination with Junshi Bio’s (HKG: 1877, SHA:…
-
Luye Pharma’s Lurbinectedin Gains Priority Review Status for SCLC Treatment
•
The Center for Drug Evaluation (CDE) website indicates that China-based Luye Pharma Group’s (HKG: 2186) lurbinectedin (LY01017), an RNA polymerase II inhibitor, is set to obtain priority review status for the treatment of metastatic small cell lung cancer (SCLC) with tumor progression during or after platinum-based chemotherapy. Development and Mechanism…
-
Guangdong Zhongsheng’s RAY1216 Receives Conditional Approval for COVID-19 Treatment
•
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced that it has received conditional marketing approval from the National Medical Products Administration (NMPA) for its drug candidate RAY1216, a 3CL protease (3CLpro) inhibitor. The drug is set to be assessed as a treatment for mild to moderate COVID-19. Mechanism…
-
Hengrui Pharmaceuticals’ HRS-5965 Receives NMPA Approval for Clinical Study in Hemolytic Anemia
•
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its investigational drug HRS-5965. The study will focus on complement-mediated hemolytic anemia, including conditions such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic…
-
Sunshine Guojian Completes Patient Enrollment for SSGJ-611 Phase II Study in Atopic Dermatitis
•
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced the completion of patient enrollment in a China-based Phase II clinical study for its SSGJ-611, an IL-4Rα monoclonal antibody (mAb). The drug is being evaluated as a treatment for moderate to severe atopic dermatitis…
-
Henlius Biotech’s Serplulimab Accepted for EMA Review for ES-SCLC Treatment
•
Shanghai Henlius Biotech (HKG: 2696) has announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for its programmed death-1 (PD-1) inhibitor, HanSiZhuang (serplulimab). The drug is filed for its first indication as a first-line treatment in combination with chemotherapy for extensive-stage small cell lung cancer…
-
AstraZeneca’s Calquence Receives Conditional Approval in China for MCL
•
AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received conditional market approval in China for its next-generation Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib). The drug is approved for the first indication in adults with mantle cell lymphoma (MCL) who have received at least one prior therapy. Clinical Trial…
-
Hinova Pharmaceuticals’ HC-1119 NDA Accepted for Review by NMPA
•
Chengdu-based biotech Hinova Pharmaceuticals Inc. (SHA: 688302) has announced that the New Drug Application (NDA) filing for its Category 1 drug HC-1119 has been accepted for review by the National Medical Products Administration (NMPA). The intended indication is for patients with metastatic castrate-resistant prostate cancer (mCRPC) who have failed to…
-
Boehringer Ingelheim Initiates Phase III FIBRONEER Studies for PDE4B Inhibitor BI 1015550
•
German pharmaceutical giant Boehringer Ingelheim (BI) has announced the first patient enrollments in the Phase III FIBRONEER studies for its phosphodiesterase 4b (PDE4B) inhibitor, BI 1015550. The studies are focused on idiopathic pulmonary fibrosis (IPF) and progressive fibrosis interstitial lung disease (PF-ILD), two conditions with limited treatment options. Global Study…
-
Advenchen Lab’s AL8326 and Hengrui’s SHR-A1811 Receive Breakthrough Therapy Designations
•
The Center for Drug Evaluation (CDE) website indicates that Advenchen Lab’s AL8326 and Hengrui Pharmaceuticals’ (SHA: 600276) SHR-A1811 have been awarded separate breakthrough therapy designations (BTDs). This recognition highlights the potential of both drugs to significantly improve the treatment of cancer patients. Advenchen’s AL8326: A Promising TKI InhibitorAdvenchen’s drug candidate…
-
Biokin’s BL-B01D1 Receives NMPA Approval for Phase II Solid Tumor Study
•
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase II clinical study assessing the efficacy and safety of its drug candidate BL-B01D1 as a treatment for solid tumors. The study will evaluate the…
-
Junshi Biosciences’ JS010 Receives NMPA Approval for Migraine Clinical Trials
•
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its JS010, an in-house developed CGRP-targeted monoclonal antibody (mAb) drug candidate for the treatment of migraines. CGRP and Its Role in MigrainesCGRP is a neuropeptide composed…
-
Immunotech Biopharm’s CAR-T-19-D2 Receives NMPA Approval for DLBCL Clinical Trial
•
China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its CAR-T-19-D2 (CAR-T-19-DNR or RC19D2) in recurrent/refractory diffuse large B-cell lymphoma (DLBCL). Mechanism of Action and Clinical NeedCAR-T-19-D2 targets the CD19…
-
Reistone Biopharma’s Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study
•
Reistone Biopharma Co., Ltd, incubated by Hengrui Pharmaceuticals (SHA: 600276) with USD 100 million in 2018, has released interim data from the 16-week mark in the Phase III QUARTZ3 study. The study is assessing the efficacy of the JAK1 inhibitor ivarmacitinib in patients with moderate to severe atopic dermatitis (AD).…
-
Yifan Pharmaceutical’s F-652 Cleared for Phase II Trial in Alcoholic Hepatitis
•
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary Evive Biotech Ltd’s F-652 has been cleared to start a Phase II clinical trial for a new indication by China’s National Medical Products Administration (NMPA). The trial will assess F-652 as a treatment for alcoholic hepatitis (AH). Mechanism…
-
Yiling Pharmaceutical’s BIO-008 Receives NMPA Approval for Clinical Trials
•
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its novel biologic product BIO-008. This marks a significant milestone in the development of the company’s innovative therapeutic biologic. Development and IndicationsBIO-008 is a monoclonal antibody…
-
Hengrui Pharmaceuticals’ SHR8028 Receives NMPA Review for Dry Eye Treatment
•
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that a market approval filing for SHR8028, an anti-inflammatory and immunomodulatory agent under development to treat dry eye, has been accepted for review by the National Medical Products Administration (NMPA) in China. Clinical Study and ResultsThe filing is based on…
